Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma

British Journal of Cancer

Volumn 90, Issue 4, 2004, Pages 770-772

  MacKie, R M ^a   Bray, C A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Hormone replacement therapy; Malignant melanoma; Oestrogen; Progestogens; Prognosis

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; ARTICLE; CANCER MORTALITY; CANCER STAGING; DRUG SAFETY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; SKIN TUMOR; SURVIVAL;

FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REGRESSION ANALYSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 1642298363     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601595     Document Type: Article

References (11)

1. Balch CM, Buzaid AC, Soong SI, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters K, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001a) Final version of American Joint Cancer Council staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648
2. Balch CM, Soong SJ, Gershenwald JE, Thomson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Dyrd D, Desmond R, Zhang Y, Liu P Lyman G, Morabito AT (2001b) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma Staging System. J Clin Oncol 19: 3622-3634
3. Ballard K (2002) Women's use of hormone replacement therapy for disease prevention. Br J Gen Practice 52: 835-837
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovich H, McTiernan A (2003) Influence of oestrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA 289: 3243-3253
5. Fletcher S, Colditz G (2002) Failure of oestrogen plus progestogen therapy for prevention. JAMA 288: 366-368
6. Joint Formulary Committee (2003) British National Formulary, 45 edn., p 352, London: British Medical Association and Royal Pharmaceutical Society of Great Britain
7. MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, Doherty VR, Vestey J (2002) Incidence of and survival from malignant melanoma in Scotland 1979-1998. Lancet 360: 587-591
8. MacKie RM, Hole DJ (1996) Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. Br Med J 312: 1125-1128
9. Million Women Study Collaborators (2003) Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362: 419-427
10. Osterlind A, Tucker MA, Stone BJ, Jensen OM (1988) The Danish case control study of cutaneous malignant melanoma. Hormonal and reproductive factors in women. Int J Cancer 42: 821-824
11. Persson I, Yuen J, Bergkvist L, Shcairer C (1996) Cancer incidence and mortality in women receiving oestrogen or oestrogen - progestin replacement therapy-long term follow up in a Swedish cohort. Int J Cancer 67: 327-332